Journal Title
Title of Journal: Curr Allergy Asthma Rep
|
Abbravation: Current Allergy and Asthma Reports
|
|
|
|
|
|
|
|
Authors: Matthew P Giannetti Juan C Cardet
Publish Date: 2016/10/31
Volume: 16, Issue: 11, Pages: 80-
Abstract
Asthma is the most common chronic respiratory disease in the USA A subset of patients with asthma have refractory symptoms persistent eosinophilic inflammation and recurrent exacerbations despite maximal medical therapy The monoclonal antibodies targeting the IL5 pathway are a new class of medications designed to target severe eosinophilic asthma There are two medications clinically available mepolizumab and reslizumab both of which target IL5 A third medication benralizumab is currently under development and targets the IL5 receptor Clinical data suggest these medications can reduce asthma exacerbations and improve lung function in patients with peripheral eosinophilia and poorly controlled asthma despite maximal medical therapy The antiIL5 medications are among the first targeted molecular therapies for asthma and will usher in an exciting new era in the treatment of severe asthma
Keywords:
.
|
Other Papers In This Journal:
|